Millennium Biltmore Hotel
Los Angeles

Downtown Los Angeles, California


SYMPOSIUM INFORMATION

>General Information
>Faculty
>Program/Schedule
>Accreditation/CME Surveys
>Registration
>Hotel Reservations

 

Supported by:
GOOD SAMARITAN HOSPITAL
Los Angeles

Officially Endorsed by:
THE HEART FAILURE SOCIETY OF AMERICA

Affiliated With:
INTERNATIONAL ACADEMY OF CARDIOLOGY

Related Conferences:


21st Annual

Heart Failure 2017
Update on Diagnosis and Therapy

PROGRAM / SCHEDULE

Saturday, April 22, 2017


>Download Brochure

Registration
6:30AM

7:00am-8:00am
Product Theatre Breakfast (Non-CME)
XARELTO to treat thrombosis and reduce thrombotic risk for patients with Non-Valvular Atrial Fibrillation and Heart Failure
Anil Bhandari, MD
Support provided by: Janssen Pharmaceuticals, Inc.

8:00am-8:10am
Introduction.
Uri Elkayam, MD

8:10am-8:30am
LDL Reduction Therapy – What is the Place of PCSK9 Inhibitors?
Pam Taub, MD

8:30am-8:50am
Diabetes and Heart Failure: A Potential Role of SGLT2 Inhibitors
Michael A Bush, MD

8:50am-9:10am
The Management of Volume Overload in Patients with Acute Decompensated Heart Failure: the Guidelines and the Art
Maria Rosa Costanzo, MD

9:10am-9:30am
New Drugs for the Management of Acute Heart Failure: Mechanisms of Action and Results of Clinical Trials
John Teerlink, MD

9:30am-9:50am
How to Maximize the use of the CardioMEMS Device for Hemodynamic Monitoring and Prevention of Heart Failure Hospitalizations
Maria Rosa Costanzo, MD

9:50am-10:10am
Coffee break/visit exhibits

10:10am-10:30am
Angiotensin Receptor Neprilysin Inhibition (ARNI): Mechanisms of Action and Rational for use in the Treatment of Heart Failure
Barry Greenberg, MD

10:30am-10:50am
Ivabradine: Role in the Management of Chronic Heart Failure
John Teerlink, MD

10:50am-11:10am
Use of Vasopressin Receptor Antagonists in the Treatment of Heart Failure
Tien Ng, PharmD

 11:10am-11:30am
Worsening of Renal Function and Hyperkalemia Associated with RAAS Inhibitors: Management Strategies.
Uri Elkayam, MD

11:30am-11:50pm
Emerging Modalities for the Management of Pulmonary Hypertension
Luanda Grazette, MD

11:50am-12:10pm
Heart failure with Preserved Ejection Fraction: New Insight into Mechanisms and Potential Therapy
Barry Borlaug, MD

12:10pm- 1:20pm
Product Theatre Lunch (Non-CME)
Putting Guidelines into Practice: New Recommendations for Optimal Treatment of Heart Failure with Reduced Ejection Fraction (HFrEF)
Barry Greenberg, MD
Support provided by: Novartis Pharmaceuticals Corporation

1:20pm-1:35pm
Break/visit exhibits

1:35pm-2:00 pm
Peripartum Cardiomyopathy - Diagnosis, Prognosis and Management
Uri Elkayam, MD

2:00pm-2:20pm
Evaluation of Dyspnea in Patients with Preserved Ejection Fraction
Barry Borlaug, MD

2:20pm-2:40pm
Use of the Wearable Cardioverter Defibrillator in Cardiac Patients at High Risk of Sudden Arrhythmic Death
Barry Greenberg, MD

2:40pm-3:00pm
The DANISH study: Should Patients with Non-Ischemic Cardiomyopathy Receive ICDs?
David Cannom, MD

3:00pm-3:20pm
Prevention of Complications in the Patients with Mechanical Assist Devices
Francisco Arabia, MD

3:20pm-3:40pm
Use of Mechanical Circulatory Support for Myocardial Recovery – Can it be Done?
Craig Selzman, MD

3:40pm-4:00pm
Coffee break/visit exhibits

4:00pm-4:20pm
Radiofrequency Ablation for Sustained Ventricular Tachycardia in Patients with Heart Failure
Anil Bhandari, MD

4:20pm-4:40pm
Challenging Cases of TAVR in High-Risk Patients with Heart Failure
Ray Matthews, MD

4:40pm-5:00pm
Transcatheter Valve in Valve: Advantages and Limitations
Steven Burstein, MD

5:00pm
Meeting Adjourned

5:30pm
Cocktail Reception/Presentation (Non-CME)
Therapies in Cardiovascular Disease:  Corlanor® (ivabradine) Product Overview & Repatha® (evolocumab) Product Overview
Pam R. Taub, MD, FACC
Support provided by: Amgen